Vital Signs - From Pill to Patch: Will Oral Administration of Neurological Drugs Change in the Future?

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on May 9, 2011, provides a strategic insight on the future of neurological drugs market.

Additionally, a company spotlight is provided for AcelRx, a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. Reimbursement and regulatory news from the FDA is also provided for week of April 18, 2011.

Table of Contents

Vital Signs - From Pill to Patch: Will Oral Administration of Neurological Drugs Change in the Future?Vital Signs: 9 May 2011This week's issue




Related Research

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.